Podcasts

Recent Episodes

August 7, 2026

Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD

August 4, 2026

An Ophthalmologist Guides Oncologists and Patients Through ADC-Related Eye Toxicities: With Sara Nunnery, MD, MSCI; and Sarah Sunshine, MD

August 3, 2026

From Trials to the Clinic: Incorporating New Advances in Metastatic TNBC

Douglas W. Sborov, MD, MS, discussed the FDA approval of isatuximab for subcutaneous injection in multiple myeloma indications.

July 31, 2026

FDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS

Solange Peters, MD, PhD, University Hospital of Lausanne

July 31, 2026

Positioning PD-L1/VEGF Bispecifics in First-Line Non–Small Cell Lung Cancer: With Solange Peters, MD, PhD

July 31, 2026

Precision Oncology, Bispecific Antibodies, and Next-Generation Targeted Therapies Are Reshaping NSCLC Care: With Chandler Park, MD; Stephen V. Liu, MD

July 30, 2026

Biomarker-Driven Shifts Signal the Next Generation of mCRC Therapies: With Tanios S. Bekaii-Saab, MD

July 30, 2026

Navigating Fixed-Durations Regimens in CLL and Improving Outcomes for High-Risk Patients: With John N. Allan, MD

Marlana M. Orloff, MD, the Alexander & Johnston Family Endowed Clinical Director in Uveal Melanoma, and associate professor at Thomas Jefferson University Hospital

July 29, 2026

Sequencing Systemic and Liver-Directed Therapy in HLA-A*02:01–Negative Metastatic Uveal Melanoma: With Marlana M. Orloff, MD

July 28, 2026

Experts Bridge Oncology and Neurology to Catch LEMS Earlier in SCLC: With Misty D. Shields, MD, PhD; Triparna Sen, MD, PhD, MS; and Ditte Primdahl, MD

All series

All Podcasts

Shubham Pant, MD, MBBS, professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, director, Clinical Research, professor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center

Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS

ByShubham Pant, MD, MBBS

December 1st 2025

Dr Pant discusses factors that drive frontline chemotherapy selection for metastatic pancreatic cancer and the role of NALIRIFOX in this treatment setting.

Jacob Sands, MD, associate chief, Lowe Center for Thoracic Oncology, Oncology Medical Director, International Patient Center, Dana-Farber Cancer Institute, assistant professor, Harvard Medical School; Shailee Shah, MD, clinical assistant professor, neurology (MS/neuroimmunology) North,western University Feinberg School of Medicine

Accurate Symptom Identification and Guidelines Support LEMS Screening and Diagnosis: With Jacob Sands, MD; and Shailee Shah, MD

ByJacob Sands, MD,Shailee S. Shah, MD

November 30th 2025

Drs Sands and Shah discuss LEMS symptom identification and what guidelines currently note as best practices for the diagnosis of this disease.

Joshua Richter, MD, associate professor, medicine, The Tisch Cancer Institute; director, Multiple Myeloma, Blavatnik Family Chelsea Medical Center, Mount Sinai

Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

ByJoshua Richter, MD

November 28th 2025

Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.

Cassie Kline, MD, MAS, attending physician, director, Clinical Research, Department of Neuro-Oncology, Children's Hospital of Philadelphia

Tovorafenib Yields Long-Term Efficacy in Pediatric Low-Grade Glioma: With Cassie Kline, MD, MAS

ByCassie Kline, MD, MAS

November 27th 2025

Dr Kline discusses longer-term efficacy data from the FIREFLY-1 study of tovorafenib in patients with relapsed/refractory pediatric low-grade glioma.

D. Ross Camidge, MD, PhD; Gideon Blumenthal, MD, vice president, Clinical Development Oncology, Merck

How An Interest in Translational Research and Drug Development Helps Evolve Regulatory Practices: With D. Ross Camidge, MD, PhD; and Gideon Blumenthal, MD

ByRoss Camidge, MD, PhD,Gideon Blumenthal, MD

November 26th 2025

Drs Camidge and Blumenthal discussed Dr Blumenthal's experience serving on both sides of the oncology regulatory divide.

Advances in ADT Personalization and Molecular Imaging Shape Updated NCCN Prostate Cancer Recommendations: With Daniel Spratt, MD

ByDaniel Eidelberg Spratt, MD

November 25th 2025

Daniel Spratt, MD, discusses key updates to the National Comprehensive Cancer Network Guidelines for prostate cancer.

Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

ByMarc S. Raab, MD

November 24th 2025

Marc S. Raab, MD, discusses evaluating teclistamab–based induction regimens in patients with newly diagnosed multiple myeloma

Harry P. Erba, MD, PhD, professor, medicine, Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, director, Leukemia Program, director, Phase I Development in Hematologic Malignancies; member, Duke Cancer Institute

FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD

ByHarry Erba, MD, PhD

November 20th 2025

Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.

Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD

ByJustin Taylor, MD

November 19th 2025

Justin Taylor, MD discusses how patients use AI to seek cancer information, its accuracy and limitations, and the implications for hematologic malignancy care.

Martha K. Terris, MD, FACS, department chair, professor, Department of Urology, Witherington Distinguished Chair in Urology, co-director, Cancer Center, Medical College of Georgia at Augusta University

Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS

ByMartha K. Terris, MD, FACS

November 18th 2025

Dr Terris discusses how the early diagnosis of bladder cancer presents a challenge, particularly in female patients, who are frequently diagnosed later.

Benjamin P. Levy, MD Kamel Abou Hussein, MD Victoria Rizk, MD

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

ByBenjamin P. Levy, MD,Victoria Rizk, MD,Kamel Abou Hussein, MD

November 17th 2025

Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

ByBenjamin P. Levy, MD,Jonathan Lee, MD, MSc

November 14th 2025

Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc discuss advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS.

Benjamin P. Levy, MD, clinical director, medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital, associate professor, oncology, Johns Hopkins University School of Medicine; Scott T. Tagawa, MD, MS, FACP, FASCO, professor, medicine and urology, Weill Cornell Medicine, attending physician, NewYork-Presbyterian – Weill Cornell Medical Center

PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

ByBenjamin P. Levy, MD,Scott T. Tagawa, MD

November 13th 2025

Drs Levy and Tagawa discuss the rapidly evolving treatment paradigms for prostate cancer and RCC live at the 43rd Annual Chemotherapy Foundation Symposium.

Ursula A. Matulonis, MD, chief, Division of Gynecologic Oncology, Brock-Wilcon Family Chair, Dana-Farber Cancer Institute, professor, medicine, Harvard Medical School; Taymaa May, MD, MSc, director, Ovarian Cancer Surgery, Division of Surgical Oncology, Brigham and Women’s Hospital, associate professor, Harvard Medical School

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

ByUrsula A. Matulonis, MD,Taymaa May, MD, MSc

November 13th 2025

In the inaugural episode of this new podcast series, Drs Matulonis and May discuss advances in gynecologic cancer surgery.

D. Ross Camidge, MD, PhD; Mark Socinski, MD, medical oncologist, executive medical director, AdventHealth Cancer Institute

How a Career Dedicated to Patient Connections and Research Advances Has Improved Lung Cancer Care: With D. Ross Camidge, MD, PhD; and Mark Socinski, MD

ByRoss Camidge, MD, PhD,Mark A. Socinski, MD

November 12th 2025

Drs Camidge and Socinski discussed the highlights of Dr Socinski's career trajectory and the personal influences that helped him arrive where he is today.

Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS

ByMartha K. Terris, MD, FACS

November 11th 2025

Dr Terris discusses disparities in treatment and outcomes for women with bladder cancer and summarized reasons for this poor prognosis.

Samantha A. Armstrong, MD, hematologist/oncologist, assistant professor, clinical medicine, Indiana University Health; Karine Tawagi, MD, hematologist/oncologist, assistant professor, clinical medicine, University of Illinois

Urothelial ESMO 2025 Updates

BySamantha A. Armstrong, MD,Karine Tawagi, MD

November 10th 2025

OncLive partnered with Two Onc Docs to review updates from the 2025 ESMO Congress on bladder cancer management that may change guidelines.

Kevin Kalinsky, MD, MS, FASCO, professor, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; director, Glenn Family Breast Center, Louisa and Rand Glenn Family Chair in Breast Cancer Research, Winship Cancer Institute

Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO

ByKevin Kalinsky, MD, MS

November 7th 2025

Dr Kalinsky discusses the treatment paradigm for HR-positive breast cancer post-CDK4/6 inhibition and the need for therapeutic advances in this setting.

Stephen Liu, MD, associate professor, medicine, Georgetown University; director, Thoracic Oncology, head, Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center

ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD

ByStephen Liu, MD

November 6th 2025

Dr Liu discusses the potential role for zidesamtinib for the treatment of patients with advanced non–small cell lung cancer harboring ROS1 rearrangements.

Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

ByHira Mian, MD

November 6th 2025

Hira Mian, MD, MSc, discusses why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic for patients with multiple myeloma.

Sikander Ailawadhi, MD, consultant, Division of Hematology/Oncology, Department of Internal Medicine, consultant, Department of Cancer Biology, professor, medicine, Mayo Clinic; Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO nurse practitioner, Multiple Myeloma Program, Cleveland Clinic

Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

BySikander Ailawadhi, MD,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

November 5th 2025

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

Medical College of Georgia at Augusta University

Bladder Cancer Symptom Awareness and Testing Are Crucial for Early Detection in Women: With Martha K. Terris, MD, FACS

ByMartha K. Terris, MD, FACS

November 4th 2025

Martha K. Terris, MD, FACS, discusses unique considerations for bladder cancer diagnosis and treatment among women

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Oncology Experts Dive Into Top Data From ESMO 2025

ByPaolo Tarantino, MD,Dana Chase, MD,Andrew W. Hahn, MD,Andrea Necchi, MD,Nicoletta Colombo, MD, PhD

November 3rd 2025

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Neal Shore, MD, FACS, medical director, Carolina Urologic Research Center

Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS

ByNeal Shore, MD, FACS

October 31st 2025

Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.

Ziad Hanhan, MD, thoracic surgeon, Hackensack Meridian Health, chairman, Surgery at Bayshore Medical Center, chief, Thoracic Surgery, Riverview Medical Center; Thomas Bauer, MD, chair, surgery, Jersey Shore University Medical Center and Hackensack Meridian Health School of Medicine; Rachel NeMoyer, MD, thoracic surgeon, Hackensack Meridian Health

Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD

ByZiad Hanhan, MD,Thomas Bauer, MD,Rachel NeMoyer, MD

October 30th 2025

Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.

Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD

ByAmit Mehta, MD

October 29th 2025

Amit Mehta, MD, discusses practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025.

Armeen Mahvash, MD, professor, Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center; assistant professor, Department of Diagnostic and Interventional Imaging, The University of Texas Medical School at Houston

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

ByArmeen Mahvash, MD

October 27th 2025

Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Vishal A. Patel, MD, FAAD, FACMS, associate professor, dermatology, GW School of Medicine & Health Sciences; director, Cutaneous Oncology Program, GW Cancer Center

FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS

ByVishal A. Patel, MD, FAAD, FACMS

October 23rd 2025

Dr Patel discusses the clinical relevance of the FDA approval of adjuvant cemiplimab for the management of high-risk cutaneous squamous cell carcinoma.

Eunice Wang, MD, professor, oncology, leader, Leukemia Clinical Disease Team, chief, leukemia, Department of Medicine, assistant member, Tumor Immunology Program, Department of Immunology, Roswell Park Comprehensive Cancer Center; associate professor, Department of Medicine, academic scholar, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD

ByEunice Wang, MD

October 22nd 2025

Dr Wang discusses the prevalence of secondary AML, unmet needs for patients with this disease, and how CPX-351 has generated improved outcomes vs 7+3.

Metastatic Breast Cancer 2025 UPDATE

BySamantha A. Armstrong, MD,Karine Tawagi, MD

October 20th 2025

In this episode, Two Onc Docs review the current management of metastatic breast cancer, emphasizing treatment strategies across molecular subtypes.

Podcasts

Recent Episodes

All series

Oncology Unplugged With Dr Chandler Park

Pediatrics

Breast Cancer Briefing

Marvels in Medicine

Talking Tumors

Biomarker Consortium

State of the Science Summits

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

OncLive on Air Powered by PER

Roundtable Discussions

Fellowship

Disparities

Rare Cancers

Women In Oncology

Conference Perspectives

OncClub

Oncology Expert Insights

FDA Approval Insights

Blood Club

Two Onc Docs

Cancer, Character, and Calling

How This Is Building Me

All Podcasts

Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS

Accurate Symptom Identification and Guidelines Support LEMS Screening and Diagnosis: With Jacob Sands, MD; and Shailee Shah, MD

Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

Tovorafenib Yields Long-Term Efficacy in Pediatric Low-Grade Glioma: With Cassie Kline, MD, MAS

How An Interest in Translational Research and Drug Development Helps Evolve Regulatory Practices: With D. Ross Camidge, MD, PhD; and Gideon Blumenthal, MD

Advances in ADT Personalization and Molecular Imaging Shape Updated NCCN Prostate Cancer Recommendations: With Daniel Spratt, MD

Teclistamab-Based Induction Is Effective and Generates MRD Negativity in Newly Diagnosed Myeloma: With Marc S. Raab, MD

FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD

Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD

Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

How a Career Dedicated to Patient Connections and Research Advances Has Improved Lung Cancer Care: With D. Ross Camidge, MD, PhD; and Mark Socinski, MD

Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS

Urothelial ESMO 2025 Updates

Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO

ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD

Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

Bladder Cancer Symptom Awareness and Testing Are Crucial for Early Detection in Women: With Martha K. Terris, MD, FACS

Oncology Experts Dive Into Top Data From ESMO 2025

Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS

Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD

Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS

Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD

Metastatic Breast Cancer 2025 UPDATE

Trending on OncLive

Phase 3 VERSATILE-003 Trial of PDS0101 in HNSCC Is Discontinued

CD24 Expression Confers Resistance to Anti–PD-1 Therapy in NSCLC, RET-TKI Dose Reductions Do Not Compromise Outcomes in RET+ Disease

FDA Advisory Committee to Review Premarket Approval Application for Multi-Cancer Early Detection Test

Dr Silverstein on the Efficacy of Abemaciclib and Hormonal Therapy in Recurrent Ovarian and Endometrial Cancer

T-DXd Plus Pertuzumab Is Approved in China for First-Line HER2+ Metastatic Breast Cancer